OraVax other research news

ORVX has been awarded a $523,740 Phase II SBIR grant by the NIH to develop its urease-based vaccine candidate to prevent and treat H. pylori infection. Ongoing preclinical and a portion of Phase II trials at the Center for Vaccine Development in Maryland will be covered by the grant. ...